NEW YORK, June 21 (GenomeWeb News) - Reaction Biology has been awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health to develop its microarray kinase screening technology for testing compounds in nanoliter reactions, the company said today.
According to Reaction Biology, the grant funds the use of its DiscoveryDot microarray technology for high-throughput kinase screening.
RBC also said that it eventually plans to expand its assay range across the human kinome.
The company did not disclose the amount of the award, but an NIH database lists a grant for Reaction Biology, entitled, "Kinome Drug Bioassay Platform," in the amount of $100,000.